(Q48457425)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16882276%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

title

Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16882276%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16882276%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Anders Grubb

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16882276%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

5

Groop L

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16882276%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

author name string

Dorkhan M

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16882276%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Frid A

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16882276%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Jovinge S

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16882276%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

language of work or name

English

0 references

publication date

1 August 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16882276%20AND%20SRC:MED&resulttype=core&format=json

Journal of Internal Medicine

28 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16882276%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

260

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16882276%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16882276%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

125-133

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16882276%20AND%20SRC:MED&resulttype=core&format=json

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

28 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

Thiazolidinedione-induced edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

Plasma brain natriuretic peptide in assessment of acute dyspnoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

Adiponectin: a relevant player in PPARgamma-agonist-mediated improvements in hepatic insulin sensitivity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

Troglitazone improves cardiac function in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

Peroxisome proliferator activator receptors (PPAR), insulin resistance, and cardiomyopathy: friends or foes for the diabetic patient with heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

The edematogenic properties of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X

The Importance of -Cell Failure in the Development and Progression of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01665.X